A Randomized, Double-Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of a New Formulation of Tetravalent Dengue Vaccine (TDV) Versus the Current Formulation of TDV in Healthy Adults (Aged 18-60 Years) in a Non-Endemic Area for Dengue
Latest Information Update: 10 Jul 2025
At a glance
- Drugs Dengue tetravalent vaccine Takeda (Primary)
- Indications Dengue
- Focus Pharmacodynamics
- Sponsors Takeda
Most Recent Events
- 10 Jul 2025 New trial record